|Assessment Status||Assessment process complete|
|Indication||For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR.|
|Full pharmacoeconomic assessment commissioned by HSE||16/06/2010|
|NCPE assessment completed||05/11/2020|
We do not recommend the reimbursement of gefitinib for first line therapy on the High Tech Drug Scheme. However, it may be considered for second line therapy.